| Address: | 26 Landsdowne St, Cambridge, MA 02139, USA |
|---|---|
| Postal code: | 02139 |
| Phone: | (857) 327-8775 |
| Website: | https://beamtx.com/ |
The best company I have had the pleasure of working with.
BEAM - Beam Therapeutics Inc. NasdaqGS - NasdaqGS Real Time Price. Currency in USD. 26 Landsdowne Street 2nd Floor Cambridge, MA 02139 United States 857 327 8775 http Beam Therapeutics Inc.'s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A...
Laser Beam Therapeutics Ltd. (LBT) is an Israeli based, life science and medical device company. We are a pioneer in the field of Low Level Laser Therapy (LLLT) for the treatment of cardiovascular indications as well as autoimmune and inflammatory diseases. Our patented, platform technology is...
Beam Therapeutics—co-founded by a trio of top-flight CRISPR researchers—is focusing on a technique known as base editing that ups the ante on CRISPR's precision by making it possible to find, remove and replace a single nucleotide base, or "letter," without affecting those surrounding it.
NEW YORK (GenomeWeb) - Beam Therapeutics announced today that it has launched with $87 million in Series A funding to develop precision genetic medicines that make edits to individual base pairs in the genome. The funding round was led by F-Prime Capital Partners and ARCH Venture...
Xin Wang. Scientist at Beam Therapeutics. Cambridge, Massachusetts305 connections. Scientist. Beam Therapeutics Inc. Dec 2018 - Present1 year 5 months.
CAMBRIDGE, Mass.--( BUSINESS WIRE)--Magenta Therapeutics (Nasdaq: MGTA) and Beam Therapeutics (Nasdaq: BEAM) today announced a non-exclusive research and clinical collaboration agreement to evaluate... more ».
Beam Therapeutics is developing a new generation of CAR-T product candidates using its proprietary base editing. The post Beam Therapeutics licenses SIRION Biotech’s LentiBOOST Technology for its CAR-T pipeline appeared first on Pharmaceutical Business review.
New & popular companies. B. Beam Therapeutics. C. Covenant Salt Company Limited.
Forbes talks with GV general partner David Schenkein about Beam Therapeutics and the company's work to address genetic diseases - https The painful blood disorder, which mostly affects Black people, is just one of thousands of rare diseases that could be cured by Beam Therapeutics'...
Beam Therapeutics. BEAM. Здравоохранение.